Indivior Solutions Pleads Guilty to Felony Charge and Indivior Entities Agree to Pay $600 Million to Resolve Criminal and Civil Investigations as Part of DOJ ’s Largest Opioid Resolution
FDA OCI, Indivior, Suboxone, film, felony, opioid, resolution, $600 million, resolve, criminal liability, civil liability, opioid, addiction, treatment, $1.4 billion, , Reckitt Benckiser, largest, withdrawal, buprenorphine, powerful opioid, film, tablet, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - July 28, 2020 Category: Medical Law Authors: DOJ Source Type: news
Indivior pays $600m in US opioid settlement
Resolution with justice department takes total paid over addiction treatment Suboxone to $2bn (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 24, 2020 Category: Pharmaceuticals Source Type: news
FDA: Doctors Should Discuss Opioid OD Antidote With Patients
FRIDAY, July 24, 2020 -- Doctors should tell patients and caregivers about the overdose antidote naloxone when they prescribe opioid painkillers such as Percocet and OxyContin and medicines to treat opioid addiction, including buprenorphine,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2020 Category: Pharmaceuticals Source Type: news
Opioid Manufacturer Indivior ’s Chief Executive Officer Pleads Guilty in Connection with Drug Safety Claims
FDA OCI, Shaun Thaxter, CEO, Indivior, guilty plea, opioid, Suboxone Film, misbranded, Reckitt Benckiser, recovery, addicts, marketing, withdrawal, treatment, buprenorphine, sales, preferred drug status, false information, misleading information (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - July 1, 2020 Category: Medical Law Authors: DOJ Source Type: news
Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder - Peckham AD, Griffin ML, McHugh RK, Weiss RD.
BACKGROUND: In the multi-site Prescription Opioid Addiction Treatment Study (POATS), the best predictor of successful opioid use outcome was lifetime diagnosis of major depressive disorder. The primary aim of this secondary analysis of data from POATS was ... (Source: SafetyLit)
Source: SafetyLit - June 24, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Baymark Health Services Acquires Two Suboxone Clinics In Louisiana
BayMark brand AppleGate Recovery expands footprint and enhances opioid addiction treatment services.(PRWeb May 15, 2020)Read the full story at https://www.prweb.com/releases/baymark_health_services_acquires_two_suboxone_clinics_in_louisiana/prweb17124788.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 15, 2020 Category: Pharmaceuticals Source Type: news
Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada - Weicker SA, Hayashi K, Grant C, Milloy MJ, Wood E, Kerr T.
OBJECTIVES: Opioid agonist therapy is the cornerstone of treatment of opioid use disorder. In Canada, buprenorphine/naloxone has recently been adopted as the first line agonist therapy given its comparable effectiveness to methadone and superior safety pro... (Source: SafetyLit)
Source: SafetyLit - November 16, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Five Pennsylvania Physicians Charged with Unlawfully Distributing Buprenorphine and Defrauding Medicare and Medicaid
opioid addiction treatment, Krishan Kumar Aggarwal, Moon Township PA, RTA, Weirton WV, Madhu Aggarwal, Bridgeville PA, Parth Bharill, Pittsburgh PA, Cherian John, Coraopolis PA, Weirton WV, Michael Bummer, Sewickley PA, Suboxone, buprenorphine, Subutex, Redirections Treatment Advocates, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - October 23, 2019 Category: Medical Law Authors: DOJ Source Type: news
Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017 - Luu H, Slavova S, Freeman PR, Lofwall M, Browning S, Slade E, Bush H.
INTRODUCTION: Buprenorphine/naloxone treatment is a highly effective treatment for opioid use disorder decreasing illicit opioid use and both all-cause and opioid-involved overdose mortality. The purpose of this study was to investigate the relationships b... (Source: SafetyLit)
Source: SafetyLit - October 16, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Embattled drugmaker Indivior raises forecasts on Suboxone strength
Indivior Plc on Tuesday raised its full-year forecasts as the embattled British drugmaker's best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats. (Source: Reuters: Health)
Source: Reuters: Health - October 15, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Indivior shares rise as it boosts guidance for a second time
Drugmaker lifted by strong performance of opioid treatment Suboxone (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 15, 2019 Category: Pharmaceuticals Source Type: news
Justice Department Obtains $1.4 Billion from Reckitt Benckiser Group in Largest Recovery in a Case Concerning an Opioid Drug in United States History
Suboxone, recovering opioid addicts, withdrawal symptoms, buprenorphine, Individor, Suboxone Film, Here to Help, discontinuance of tablet Suboxone, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - August 8, 2019 Category: Medical Law Authors: DOJ Source Type: news
MedicaSafe Turns Attention to Opioid Addiction
One of MedicaSafe’s primary goals is to develop products for high-risk medication management. So it makes sense for the New York-based company to focus on opioid addiction, which claims the lives of more than 130 people every day in the U.S. (According to the U.S. Department of Health and Human Services).
The New York-based company recently received $1 million Small Business Innovation Research grant from the National Institute of Health, with a specific focus on opioid use disorder (OUD).
The funding will support a clinical trial to examine the effect of MedicaSafe’s drug-device combina...
Source: MDDI - July 19, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Digital Health Source Type: news
Indivior loses appeal to block generic Suboxone opioid treatments
A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. (Source: Reuters: Health)
Source: Reuters: Health - July 12, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Reckitt to pay $1.4B in opioid settlement
Reckitt Benckiser Group will pay up to $1.4 billion to settle U.S. investigations into whether its former pharma unit organized a multibillion-dollar fraud to drive up sales of its opioid-addiction treatment, Suboxone. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 12, 2019 Category: Pharmaceuticals Source Type: news
